Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H15BrN6O |
Molecular Weight | 435.277 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cc1cc(cc(C)c1Oc2c(c(N)nc(Nc3ccc(cc3)C#N)n2)Br)C#N
InChI
InChIKey=PYGWGZALEOIKDF-UHFFFAOYSA-N
InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.drugs.com/ppa/etravirine.html | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000900/WC500034183.pdf | http://www.wikidoc.org/index.php/Etravirine
Curator's Comment:: description was created based on several sources, including:
https://www.drugs.com/ppa/etravirine.html | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000900/WC500034183.pdf | http://www.wikidoc.org/index.php/Etravirine
Etravirine (formerly known as TMC125) is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1). It directly binds reverse transcriptase and consequently blocks DNA-dependent and RNA-dependent polymerase activity. In combination with other antiretroviral agents, it is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents. The most common adverse events (incidence > 10%) of any intensity that occurred at a higher rate than placebo are rash and nausea. Etravirine should not be co-administered with the following antiretrovirals: Tipranavir/ritonavir, fosamprenavir/ritonavir, atazanavir/ritonavir; Protease inhibitors administered without ritonavir; NNRTIs.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4302 |
24.2 µM [IC50] | ||
38.4 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | INTELENCE Approved UseINTELENCE® Registered trademark of Tibotec Pharmaceuticals, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents. This indication is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE®. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t Launch Date1.20061441E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
296.74 ng/mL |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: DARUNAVIR |
ETRAVIRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4531.53 ng × h/mL |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: DARUNAVIR |
ETRAVIRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
41 h |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: DARUNAVIR |
ETRAVIRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.1% |
200 mg 2 times / day steady-state, oral dose: 200 mg route of administration: Oral experiment type: STEADY-STATE co-administered: DARUNAVIR |
ETRAVIRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg 2 times / day multiple, oral Highest studied dose Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: F6 |
unhealthy, 29–63 n = 79 Health Status: unhealthy Condition: HIV-1 infection Age Group: 29–63 Sex: M+F Population Size: 79 Sources: Page: F6 |
|
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.5 |
unhealthy n = 599 Health Status: unhealthy Condition: HIV-1 infection Population Size: 599 Sources: Page: p.5 |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (2.2%) Sources: Page: p.5 |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
Disc. AE: Reaction skin, Stevens-Johnson syndrome... AEs leading to discontinuation/dose reduction: Reaction skin (severe|grade 4|grade 5) Sources: Page: p.1Stevens-Johnson syndrome (severe|grade 4|grade 5) Hypersensitivity reaction (severe|grade 4|grade 5) Toxic epidermal necrolysis (severe|grade 4|grade 5) Erythema multiforme (severe|grade 4|grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rash | 2.2% Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.5 |
unhealthy n = 599 Health Status: unhealthy Condition: HIV-1 infection Population Size: 599 Sources: Page: p.5 |
Erythema multiforme | severe|grade 4|grade 5 Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
Hypersensitivity reaction | severe|grade 4|grade 5 Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
Reaction skin | severe|grade 4|grade 5 Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
Stevens-Johnson syndrome | severe|grade 4|grade 5 Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
Toxic epidermal necrolysis | severe|grade 4|grade 5 Disc. AE |
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: HIV-1 infection Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds. | 2004 |
|
Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. | 2004 |
|
TMC125: important one-year trial now recruiting in U.S. | 2004 Apr 30 |
|
Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. | 2004 May 15 |
|
Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. | 2004 May 6 |
|
A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. | 2004 Oct |
|
New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections. | 2004 Oct |
|
HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. | 2004 Sep |
|
New drugs. | 2005 Jul |
|
Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. | 2005 Jun |
|
Emerging anti-HIV drugs. | 2005 May |
|
The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. | 2005 May 25 |
|
TMC125: new results, large phase III trial begins. | 2005 Oct-Nov |
|
Report from the 13th retrovirus conference. New data on TMC114 and TMC125. | 2006 Apr |
|
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | 2006 Feb |
|
The clinical pharmacology of antiretrovirals in development. | 2006 Jun |
|
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). | 2006 Nov |
|
Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. | 2007 |
|
Antiretroviral treatment of HIV infection: Swedish recommendations 2007. | 2007 |
|
Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. | 2007 Dec |
|
TMC125 (etravirine), a second generation non-nucleoside reverse transcriptase inhibitor. | 2007 Feb |
|
Expanded drug access: etravirine (formerly TMC-125). | 2007 Jan |
|
Anti-HIV agents. Brain side effects not common with etravirine. | 2007 Jan |
|
Anti-HIV agents. Effectiveness of etravirine in treatment-experienced PHAs. | 2007 Jan |
|
Anti-HIV agents. Etravirine--interactions with some medications. | 2007 Jan |
|
Anti-HIV agents. The need for etravirine (TMC125). | 2007 Jan |
|
Gateways to clinical trials. | 2007 Jan-Feb |
|
Gateways to clinical trials. | 2007 Jul-Aug |
|
Drug resistant HIV. | 2007 Jun 2 |
|
Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis. | 2007 Mar 30 |
|
Modelling-based prediction of clinical benefits from etravirine in the TMC125-C223 trial. | 2007 Mar-Apr |
|
Advances in HIV therapeutics: the 14th CROI. | 2007 May |
|
FDA accepts NDA for priority review of TMC125. | 2007 Oct |
|
Antiviral drugs in the treatment of AIDS: what is in the pipeline ? | 2007 Oct 15 |
|
NDA submitted for TMC125. | 2007 Sep |
|
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Advances in antiretroviral therapy. | 2008 Apr-May |
|
Follow-up of a multi-drug resistant HIV-1 infected patient successfully treated with darunavir and etravirine. | 2008 Aug |
|
FDA approves new HIV drug after priority review. | 2008 Feb |
|
The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. | 2008 Feb 1 |
|
3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. | 2008 Feb 1 |
|
How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. | 2008 Jul |
|
New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. | 2008 Jul |
|
Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection. | 2008 Jun |
|
FDA approval: etravirine. | 2008 Mar |
|
Pharmacokinetic and pharmacodynamic study of the concomitant administration of methadone and TMC125 in HIV-negative volunteers. | 2008 Mar |
|
Successful rescue therapy with Raltegravir (MK-0518) and Etravirine (TMC125) in an hiv-infected patient failing all four classes of antiretroviral drugs. | 2008 May |
|
Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor resistance? | 2008 May 11 |
|
Shifting paradigms: the resistance profile of etravirine. | 2008 Oct |
|
A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. | 2008 Sep |
|
Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. | 2008 Sep |
Patents
Sample Use Guides
200 mg (two 100 mg tablets) taken twice daily following a meal
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15561844
TMC125, was highly active against wild-type HIV-1 (50% effective concentration [EC50] = 1.4 to 4.8 nM) and showed some activity against HIV-2 (EC50 = 3.5 microM). TMC125 also inhibited a series of HIV-1 group M subtypes and circulating recombinant forms and a group O virus.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
INTELENCE (AUTHORIZED: HIV INFECTIONS)
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
NCI_THESAURUS |
C97453
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
WHO-VATC |
QJ05AG04
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
NDF-RT |
N0000175463
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
NDF-RT |
N0000009948
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
LIVERTOX |
390
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
WHO-ATC |
J05AG04
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
||
|
NDF-RT |
N0000175460
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
193962
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
269055-15-4
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
M5205
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | Merck Index | ||
|
ETRAVIRINE
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
269055-15-4
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
8303
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
CHEMBL308954
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
C451734
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
C73195
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
SUB25650
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
0C50HW4FO1
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
Etravirine
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
475969
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | RxNorm | ||
|
1115
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY | |||
|
DB06414
Created by
admin on Sat Jun 26 05:19:26 UTC 2021 , Edited by admin on Sat Jun 26 05:19:26 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)